Dendreon Overview
Work Here? Claim your Free Employer Profile- www.dendreon.com
- Seal Beach, CA
- 501 to 1000 Employees
- 2010
- Company - Private
- Biotech & Pharmaceuticals
- $100 to $500 million (USD)
Competitors: Unknown
Dendreon’s PROVENGE® (sipuleucel-T), which was approved by the U.S. Food and Drug Administration in April 2010, is the only cellular immunotherapy1 cancer treatment available. Dendreon is working to expand the application of its technology to discover, develop, manufacture and ...
Mission: Making the battle against cancer personal through immunotherapy treatments that extend lives
What are your colleagues talking about?
Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously.
Dendreon Reviews
3.4
★★★★★
Recommend to a Friend
★★★★★
"CFO of Dendreon CN"
Apr 6, 2023 - Finance/Accouting
Recommends
Neutral Outlook
Pros
build finance team in Shanghai ChinaCons
It's a biopharmaceutical company, a very promising industry in China.
Dendreon Interviews
Experience
Positive55%
Negative21%
Neutral24%
Getting an Interview
Applied online49%
Employee Referral17%
Recruiter15%
Difficulty
2.7
AverageHardAverageEasy
Manufacturing Operations Associate Interview
Anonymous Employee in United StatesAccepted OfferPositive ExperienceAverage InterviewInterview
I believe that the interview was thorough, and the interviewers were professional while creating a comfortable environment. I was pleased with the ease of the interview process. They explained the job requirements, answered my questions to the best of their ability, and significantly increased my understanding of what I would be doing in my position.InterviewThey asked me about my prior experience and how I worked with others.
Answer Question
See All 61 interviews
Company Updates
November 23, 2021
Company News
Big news, as Dendreon signs its first CMS (CMO/CDMO) partnership!
Dendreon Pharmaceuticals and Shoreline Biosciences Announce CMC and Manufacturing Alliance to Advance the Future of iPSC Cellular Therapy
www.businesswire.com
June 17, 2021
Company News
SEAL BEACH, Calif.--(BUSINESS WIRE)--Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of cellular immunotherapy, has established and invested in its new contract manufacturing and services division to bring late-stage clinical assets through to commercialization. Leveraging its extensive manufacturing, process development and logistics expertise, Dendreon now offers end-to-end manufacturing of complex cell therapies and patient logistics for partner programs.
“We are enabling the future of immunotherapy and supporting an unmet need in the market with immediate access to capacity and expertise”
Tweet this
“Innovative cell therapies have the potential to change how we treat serious diseases, but there is currently insufficient capacity to meet anticipated industry demand,” said Jason O’Neill, Chief Executive Officer of Dendreon. “With more than a decade of proven expertise in cell therapy manufacturing and an established supply chain and logistics infrastructure, we have invested in an offering that fills an immediate market need i
Dendreon Pharmaceuticals Invests in Contract Manufacturing and Patient Services for Cell Therapy Partners
www.businesswire.com
Dendreon Awards & Accolades
- ACG Corporate Award for Reinventing, Orange County Association for Corporate Growth, 2019
Popular Careers with Dendreon Job Seekers
Dendreon FAQ
(33 Questions)
All answers shown come directly from Dendreon Reviews and are not edited or altered.
What are perks and other benefits like at Dendreon?
...Good benefits and working hours...
March 1, 2021
People Also Ask about Dendreon
To get a job at Dendreon, browse currently open positions and apply for a job near you. Once you get a positive response, make sure to find out about the interview process at Dendreon and prepare for tough questions.
Work at Dendreon? Share Your Experiences
Dendreon
Click to Rate
